The estimated Net Worth of Rhonda Farnum is at least $3.33 Milión dollars as of 10 July 2024. Ms Farnum owns over 4,000 units of Theravance Biopharma Inc stock worth over $2,721,317 and over the last 3 years she sold TBPH stock worth over $172,527. In addition, she makes $435,518 as Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs at Theravance Biopharma Inc.
Sign up
Ms Farnum TBPH stock SEC Form 4 insiders trading
Ms has made over 8 trades of the Theravance Biopharma Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 4,000 units of TBPH stock worth $36,000 on 10 July 2024.
The largest trade she's ever made was selling 4,000 units of Theravance Biopharma Inc stock on 10 July 2024 worth over $36,000. On average, Ms trades about 930 units every 45 days since 2021. As of 10 July 2024 she still owns at least 335,965 units of Theravance Biopharma Inc stock.
You can see the complete history of Ms Farnum stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Rhonda F. Farnum biography
Rhonda F. Farnum is the Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs at Theravance Biopharma Inc.
What is the salary of Ms Farnum?
As the Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs of Theravance Biopharma Inc, the total compensation of Ms Farnum at Theravance Biopharma Inc is $435,518. There are 10 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of $5,932,410.
How old is Ms Farnum?
Ms Farnum is 56, she's been the Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs of Theravance Biopharma Inc since . There are 15 older and 11 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.
What's Ms Farnum's mailing address?
Rhonda's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BLVD, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Theravance Biopharma Inc
Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva, a Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
What does Theravance Biopharma Inc do?
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
What does Theravance Biopharma Inc's logo look like?
Complete history of Ms Farnum stock trades at Theravance Biopharma Inc
Theravance Biopharma Inc executives and stock owners
Theravance Biopharma Inc executives and other stock owners filed with the SEC include:
-
Rick Winningham,
Chairman of the Board, Chief Executive Officer -
Andrew Hindman,
Chief Financial Officer, Senior Vice President -
Bradford Shafer,
Executive Vice President, General Counsel, Secretary -
Brett Haumann,
Senior Vice President, Clinical Development and Chief Medical Officer -
Frank Pasqualone,
Senior Vice President and Chief Commercial Operations Officer -
Philip Worboys,
Senior Vice President - Research and Translational Science -
Rick E. Winningham M.B.A.,
Chairman & CEO -
Andrew Asa Hindman,
Sr. VP & CFO -
Bradford J. Shafer,
Exec. VP, Gen. Counsel & Sec. -
Andrew Asa Hindman M.B.A,
Sr. VP & CFO -
Rhonda F. Farnum,
Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs -
William Young,
Lead Independent Director -
Burton Malkiel,
Independent Director -
Donal O'Connor,
Independent Director -
Dean Mitchell,
Independent Director -
Susan Molineaux,
Independent Director -
Eran Broshy,
Independent Director -
Laurie Alsup,
Independent Director -
George Whitesides,
Independent Director -
Robert Gunderson,
Director -
Deepika Pakianathan,
Independent Director -
Vijay Sabesan,
Senior Vice President - Technical Operations -
Kenneth Pitzer,
Senior Vice President - Product Strategy and Commercial Planning -
Ann Brady,
President - Theravance Biopharma Ireland Limited -
Dr. Ann B. Brady Ph.D.,
Pres of Theravance Biopharma Ireland Limited -
Dr. Richard A. Graham Ph.D.,
Sr. VP of Devel. -
Daniel Long,
Head of Medicinal Chemistry -
Dr. Kenneth R. Pitzer,
Sr. VP of Product Strategy & Commercial Planning -
Dr. Phillip D. Worboys,
Sr. VP of Research & Translational Science -
Dennis O. Driver,
Sr. VP of HR, Organizational and Leadership Devel. -
Gail B. Cohen,
VP of Corp. Communications & Investor Relations -
Jeremy T Grant,
-
Renee D Gala,
VP-Finance -
Peter S Ringrose,
Director -
Junning Lee,
Sr. VP, Technical Operations -
Sharathchandra S Hegde,
SVP, Research -
Henrietta Fore,
Director -
Shehnaaz Suliman,
SVP, Corp Dev & Strategy -
Jeffrey David Jonker,
Senior VP, Corp. & Bus. Dev. -
Michael G Atieh,
Director -
Leonard M Blum,
Sr VP, Chief Comm. Officer -
Inc. Innoviva,,
10% owner -
Mathai Mammen,
SVP, Research & Early Clin Dev -
Rhonda Farnum,
SVP, COMM & MEDICAL AFFAIRS -
Richard A Graham,
SVP, RESEARCH & DEVELOPMENT -
Plc Gsk,
-
Aziz Sawaf,
SVP & CHIEF FINANCIAL OFFICER -
Brett A. Grimaud,
SVP, GEN COUNSEL AND SECRETARY -
Susannah Gray,
-
Aine Miller,
SVP, DEV & HEAD OF IRE OFFICE -
Eli Samaha,
10% owner